News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Automakers are applying for Commerce Department licenses to sell China-assembled cars amid a U.S. ban on Chinese connected-vehicle software.
  • The U.S. Strategic Petroleum Reserve fell to 340.3 million barrels, its lowest level since 1983, after a planned 8.9 million-barrel drawdown.
  • Lockheed Martin won a $514 million Space Force contract to build two GPS IIIF satellites, expanding its GPS IIIF production pipeline.
  • Ukraine opened the first phase of EU accession talks on 'fundamentals', formally starting membership negotiations.
  • Fitch affirmed China's 'A' rating with a stable outlook, citing durable growth despite medium-term fiscal pressures.
  • S&P upgraded Victoria's Secret's outlook to positive after stronger-than-expected Q1 sales and margin improvement.

Latest Articles

Keefe, Bruyette & Woods Elevates Horizon Bancorp Price Target to $21 Following Robust Quarterly Earnings

Keefe, Bruyette & Woods Elevates Horizon Bancorp Price Target to $21 Following Robust Quarterly Earnings

Keefe, Bruyette & Woods raised its price target on Horizon Bancorp to $21 from $19, endorsing an Outperform rating after the bank reported better-than-expected earnings. The bank’s higher pre-provision net revenue and net interest margin contributed to stronger top-line performance. Updated guidance and optimistic margin outlook prompted increased …

RBC Capital Raises Definium Therapeutics Price Target, Citing Growth Potential in Mental Health Drug Development

RBC Capital Raises Definium Therapeutics Price Target, Citing Growth Potential in Mental Health Drug Development

RBC Capital has increased the price target for Definium Therapeutics Inc to $36 from $20 and reaffirmed an Outperform rating. This adjustment is based on heightened expectations for the commercial success of Definium’s lead candidate, DT120, currently in late-stage trials for generalized anxiety disorder. The company’s market value stands near $1.6…

Evercore ISI Revises CSX Price Target to $40 Amid Mixed Financial Results

Evercore ISI Revises CSX Price Target to $40 Amid Mixed Financial Results

Evercore ISI has reduced its price objective for CSX to $40 from $41 while keeping an Outperform rating on the company's stock. The adjustment follows CSX's fourth-quarter 2025 earnings report, which revealed earnings per share below estimates and volumes and yields underperforming across segments. Despite these challenges, the company forecasts mo…

ECB’s Kocher Advocates Prudence in Policy Amendments Amid Persistent Uncertainty

ECB’s Kocher Advocates Prudence in Policy Amendments Amid Persistent Uncertainty

Martin Kocher, the president of the Austrian central bank, has urged the European Central Bank (ECB) to exercise caution before implementing policy changes in response to ongoing uncertainties. Speaking to German media, Kocher highlighted the need to avoid premature commitments that could complicate future communications, especially when inflation …

Kocher Urges Prudence in ECB Policy Amid Rising Geopolitical Uncertainties

Kocher Urges Prudence in ECB Policy Amid Rising Geopolitical Uncertainties

Austrian central bank governor Martin Kocher has emphasized a measured approach for the European Central Bank (ECB) when considering policy adjustments in response to heightened geopolitical tensions. Speaking in an interview with a German media outlet, Kocher highlighted the risks of premature moves absent clear inflationary direction, stressing t…